Evidence map›Paper›PMID 22284022›Full record

Trial reportJournal of affective disorders2012

Do sub-syndromal manic symptoms influence outcome in treatment resistant depression in adolescents? A latent class analysis from the TORDIA study.

Fadi T Maalouf, Giovanna Porta, Benedetto Vitiello, Graham Emslie, Taryn Mayes, Gregory Clarke, Karen D Wagner, Joan Rosenbaum Asarnow, Anthony Spirito, Martin Keller and 5 more

Erratum issued Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of affective disorders, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT00018902 (Treatment of SSRI-Resistant Depression in Adolescents), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00018902 phase2 / phase3completednot on this map

Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)

TypeinterventionalSponsorUniversity of PittsburghRan2001 to 2007Enrolled334ConditionsDepressionArmsFluoxetine, Venlafaxine, Cognitive Behavioral Therapy (CBT), Citalopram
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trajectories of Symptom Change in the Treatment for Adolescents With Depression Study.Journal of the American Academy of Child and Adolescent Psychiatry · 2019
    Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Annual Research Review: Defining and treating pediatric treatment-resistant depression.Journal of child psychology and psychiatry, and allied disciplines · 2020
    Review
  13. Article
  14. Antidepressant-Induced Activation in Children and Adolescents: Risk, Recognition and Management.Current problems in pediatric and adolescent health care · 2018
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Bipolar disorder in children and adolescents.Child and adolescent mental health · 2013
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 2 countries.

Fadi T MaaloufAmerican University of Beirut, Lebanon.
Giovanna Porta
Benedetto Vitiello
Graham Emslie
Taryn Mayes
Gregory Clarke
Karen D Wagner
Joan Rosenbaum Asarnow
Anthony Spirito
Martin Keller
Boris Birmaher
Neal Ryan
Wael Shamseddeen
Satish Iyengar
David Brent
University of Pittsburgh · USJohn Brown University · USThe University of Texas Medical Branch at Galveston · USKaiser Permanente · USNational Institutes of Health · USRosalind Franklin University of Medicine and Science · USThe University of Texas at Austin · USUniversity of California, Los Angeles · US

Funding

Core--Research network developmentP30MH066371 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BRENT, DAVID A. · 2002 to 2006
$8.2M
TREATMENT OF SSRI RESISTANT DEPRESSION IN ADOLESCENTSU01MH061835 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BRENT, DAVID A. · 2000 to 2006
$3.3M
TREATMENT OF SSRI RESISTANT DEPRESSION IN ADOLESCENTSU01MH061869 · NIMH · KAISER FOUNDATION RESEARCH INSTITUTE · PI CLARKE, GREGORY N · 2000 to 2006
$2.8M
TREATMENT OF SSRI RESISTANT DEPRESSION IN ADOLESCENTSU01MH061856 · NIMH · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI WAGNER, KAREN D · 2000 to 2006
$1.9M
TREATMENT OF SSRI RESISTANT DEPRESSION IN ADOLESCENTSU01MH061958 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI EMSLIE, GRAHAM J. · 2000 to 2006
$1.8M
TREATMENT OF SSRI RESISTANT DEPRESSION IN ADOLESCENTSU01MH061864 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ASARNOW, JOAN ROSENBAUM · 2000 to 2006
$1.5M
TREATMENT OF SSRI-RESISTANT DEPRESSION IN ADOLESCENTSU01MH062014 · NIMH · BROWN UNIVERSITY · PI KELLER, MARTIN B · 2000 to 2006
$1.5M
NIMH NIH HHS MH61835NIMH NIH HHS MH61856NIMH NIH HHS MH61864NIMH NIH HHS MH61869NIMH NIH HHS MH61958NIMH NIH HHS MH62014NIMH NIH HHS MH66371NIMH NIH HHS P30 MH066371NIMH NIH HHS U01 MH061835NIMH NIH HHS U01 MH061856NIMH NIH HHS U01 MH061864NIMH NIH HHS U01 MH061869NIMH NIH HHS U01 MH061958NIMH NIH HHS U01 MH062014
6 · The paper itself

Abstract

backgroundTo identify distinct depressive symptom trajectories in the TORDIA study and determine their correlates.

methodsLatent Class Growth Analysis (LCGA) using the Children's Depression Rating Scale-Revised (CDRS-R) through 72 weeks from intake.

results3 classes were identified: (1) little change in symptomatic status ("NO"), comprising 24.9% of participants, with a 72-week remission rate of 25.3%; (2) slow, steady improvement ("SLOW"), comprising 47.9% of participants, with a remission rate of 60.0%, and (3) rapid symptom response ("GO"), comprising 27.2% of participants, with a remission rate of 85.7%. Higher baseline CDRS-R (p<0.001) and poorer functioning (p=0.03) were the strongest discriminators between NO and GO. Higher baseline CDRS (p<0.001) and scores on the Mania Rating Scale (MRS) (p=0.01) were the strongest discriminators between SLOW and GO. Other variables differentiating GO from both NO and from SLOW, were better baseline functioning, lower hopelessness, and lower family conflict. Both NO and SLOW showed increases on the MRS over time compared to GO (ps ≤ 0.04), and increasing MRS was strongly associated with lack of remission by 72 weeks (p=0.02). LIMITATIONS: High rate of open treatment by the end of the follow-up period creates difficulty in drawing clear inferences about the long-term impact of initial randomization.

conclusionAlong with depressive severity, sub-syndromal manic symptoms, at baseline, and over time emerged as important predictors and correlates of poor outcome in this sample. Further research is needed on the treatment of severe depression, and on the assessment and management of sub-syndromal manic symptoms in treatment resistant depression.

Indexed as

AdolescentBipolar DisorderChildCognitive Behavioral TherapyDepressive Disorder, Treatment-ResistantFemaleFollow-Up StudiesHumansMajor Depressive DisorderMaleSelective Serotonin Reuptake InhibitorsSyndromeSelective Serotonin Reuptake Inhibitors

Identifiers

PMID22284022
PMCPMC3621087
OpenAlexW2140895906

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.